Coronary heart disease and stroke are the two leading causes of death worldwide and by the year 2030, they are projected to account for nearly 25% of deaths. Association of hypercholesterolemia with these two conditions makes it a major contributor to the global disease burden and cardiovascular disease associated with mortality and morbidity.
Hypercholesterolemia is a condition wherein the combination of genetic mutations and environmental factors like an excessive amount of fat in diet, obesity and physical inactivity lead to elevated serum cholesterol levels. Familial hypercholesterolemia is a condition where a mutation in genes LDLR, APOB, PCSK genes cause an elevation in levels of total cholesterol and LDL-C. Diagnosis of FH needs the following criteria - increased cholesterol levels, physical stigmata e.g tendon xanthomas or evidence of these signs in first or second-degree relatives and a family history of premature coronary artery disease. In approximately 60% the mutation is negative in the above-mentioned genes, leading to a polygenic cause of hypercholesterolemia. Hypercholesterolemia of genetic origin negative for mutations in LDLR, APOB, PCSK9 genes is Polygenic hypercholesterolemia. The mutation in several small LDL raising alleles ( single nucleotide polymorphism genes) leads to polygenic hypercholesterolemia which can be determined by genetic score.
Familial hypercholesterolemia leads to early development of atherosclerotic cardiovascular disease which include coronary artery disease, transient ischemic attack, stroke, peripheral artery disease. The risk is lower in polygenic variety than monogenic type.
Mutations in several small LDL raising alleles cause polygenic hypercholesterolemia. Polygenic hypercholesterolemia is asymptomatic. It neither causes severe atherosclerosis nor presents with cardiovascular disease at an early age. Polygenic hypercholesterolemia is asymptomatic and is usually diagnosed during a routine screening and after further evaluation of abnormal lab values. Since it is genetically inherited, it runs in families. But lifestyle factors also play a major role such as a diet rich in saturated fat, lack of exercise, etc.
In United States, 53% have elevated LDL-C levels which is more than 100 million of the US population. Only 50% of them receive treatment and less than 35% achieve adequate control of the blood cholesterol levels. This places them at increased risk for atherosclerotic cardiovascular disease.
Further LDL-C is more commonly elevated in females(32%) than males (31%). Ethnic differences include - Hispanic males (38.8%), non-Hispanic black males(30.7%), non-hIspanic white males (29.4%). Prevalence is more among Asian Indians, Filipinos, Japanese, and Vietnamese than among whites.
Mutations in LDL-C affecting genes (SNPs) cause polygenic hypercholesterolemia. Global Lipid Genetic Consortium has identified about 95 loci which affect LDL-C levels. These loci contribute not only to variation in lipid traits but also to extreme lipid phenotypes. Accumulation of several small LDL-C raising alleles leads to polygenic hypercholesterolemia. The 12 SNPs used in the score is shown below.
Global Lipid Genetic Consortium 12 SNP LDL-C Gene Score, showing the LDL-C-raising allele and the published raising effect (in mmol/l).
Once these SNPs have been genotyped, they are entered into a scoring scheme to quantify their cumulative effect on the lipid trait. These scores sum the expected effect of each individual SNP in a given patient, yielding a polygenic SNP score (also called a ‘polygenic risk score’ or ‘polygenic trait score’) that can be compared to a normolipidaemic population. An individual with a high polygenic score, e.g., >90th percentile for the population, would be predisposed to develop clinically apparent dyslipidaemia.
After VLDL is synthesized from free fatty acids and triglycerides in the liver, it is cleaved into IDL(intermediate density lipid) and LDL. LDL is a major cholesterol-containing lipoprotein which causes atherosclerosis. LDL receptor in the liver regulates the serum cholesterol levels.
A decrease in serum cholesterol levels causes increased expression of hepatic LDL which causes greater clearance of dietary cholesterol. Increased dietary fatty acids lead to decreased expression of hepatic LDL receptors and increase serum cholesterol levels. High dietary cholesterol suppresses endogenous cholesterol production. High dietary fat will result in high serum cholesterol levels.
Polygenic hypercholesterolemia is asymptomatic and is usually detected during routine screening. It is more common in individuals with a family history, but also lifestyle factors also play a major role. History should include cigarette smoking, diabetes mellitus, and sedentary lifestyle assessment since they also contribute to the clinical manifestation of the disease.
The current recommendation for screening for hypercholesterolemia is starting from age 21 if they have risk factors (level B). Risk factors include smoking, high blood pressure, diabetes mellitus, BMI>30, family history of premature cardiovascular disease or previous personal history of atherosclerotic cardiovascular disease). It is repeated every 5 yrs, if normal. HDL and total cholesterol levels are measured if non-fasting which can be used to estimate atherosclerotic cardiovascular disease risk score. If the cholesterol levels are moderately elevated, dietary changes are recommended for 4-6months. If high the patient is started on lipid-lowering therapy.
Strong recommendation(Level A) is from age 35 for males and age 45 for females.
Determination of LDL-C mutation causing alleles and determination of genetic score is recommended to detect polygenic hypercholesterolemia.
The degree of thickening in the carotid artery as measured by ultrasound, as well as coronary calcium score is less in polygenic hypercholesterolemia when compared to monogenic hypercholesterlemia. 
Statins have significantly reduced coronary artery disease rates, TIA rates and strokes.
Statins inhibit the enzyme HMG-CoA reductase. They decrease LDL, thereby reducing mortality.
Examples include - Atorvastatin, rosuvastatin, pitavastatin decrease LDL by >50% (high intensity statins)
Lovastatin, simvastain, decrease LDL moderately (moderate intensity statins, decrease LDL between by 30%-50%)
Fluvavastatin, pravastatin decrease LDL mildly (decrease LDL-C by <30%)
Bile acid sequestrants
Cholestyramine, cholesterol, cloesevelam.
They bind to bile acids and decrease absorption of cholesterol and increase LDL receptors.
PCSK9 inhibitors - Alirocumab and Evolocumab cause a decrease in LDL cholesterol levels through decreased degradation of LDL receptors.
Ezetimibe - It selectively inhibits cholesterol absorption in the intestine by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein.
Exercise along with decreased intake of dietary saturated fat aid in decreasing the prevalence of high serum cholesterol and atherosclerotic cardiovascular disease. 
Familial Hypercholesterolemia (tendon xanthomas)
Hypertryglyceridemia ( eruptive xanthomas)
Secondary hypercholesterolemia in the following conditions
- Liver disease
- Nephrotic syndrome
- Chronic renal disease
- Systemic lupus erythematosus
- Cigarette smoking
- Storage diseases like Gaucher disease, Von Gierke disease
Side effects of statins include -
statin associated myalgia
statin induced myopathy ( management includes decreasing the dose, weekly long acting statin, start a different statin, or switch to other class of hypolipidemic agent)
rhabdomyolysis (needs immediate treatment to decrease renal injury, evaluate for other co-morbidities, triggering factor, assess for medications which interfere with metabolism of statins)
statin associated autoimmune myopathy ( discontinue statin)
new onset diabetes mellitus(risk is more in patients with metabolic syndrome- it is discussed with the patient before stating the drug)
memory and cognition changes
gastrointestinal side effects
PCSK9 inhibitors - side effects include nasopharyngitis, injection site reactions.
NPC1L1 blocker - ezetimibe
Side effects - headache, URIs, myalgia, fatigue, weakness, increase in liver enzymes, diarrhea.
myopathy (when used with statin in patients >65yrs, renal impairment, hypothyroidism)
Bile acid sequestrants
side effects - They decrease absorption of fat soluble vitamins, constipation, bloating, indigestion, vomiting.
Transient ischemic attack (TIA)
Coronary artery disease (CAD)
Peripheral artery disease (PAD)
Dietary recommendations on low fat and low cholesterol diet is recommended
Polygenic hypercholesterolemia is an autosomal dominant familial condition wherein mutation in several small LDL raising alleles leads to an elevation in serum cholesterol levels. The condition is asymptomatic and is usually detected on routine screening. Other causes for increased serum cholesterol include familial hypercholesterolemia, hypercholesterolemia secondary to liver disease, hypothyroidism, nephrotic syndrome, chronic renal disease, hypopituitarism.
While PCP plays an important role in evaluation and treatment, it is important to consult with an inter-professional team of specialists which include cardiologists and geneticists. The pharmacist will ensure whether the patient is on a hypolipidemic agent.
Proper evaluation and treatment will lead to a reduction in TIA, strokes, CAD, and PVD.
|||Berberich AJ,Hegele RA, The role of genetic testing in dyslipidaemia. Pathology. 2019 Feb; [PubMed PMID: 30558903]|
|||Futema M,Bourbon M,Williams M,Humphries SE, Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. Atherosclerosis. 2018 Oct; [PubMed PMID: 30270085]|
|||Sharifi M,Futema M,Nair D,Humphries SE, Genetic Architecture of Familial Hypercholesterolaemia. Current cardiology reports. 2017 May; [PubMed PMID: 28405938]|
|||Sharifi M,Futema M,Nair D,Humphries SE, Polygenic Hypercholesterolemia and Cardiovascular Disease Risk. Current cardiology reports. 2019 Apr 22; [PubMed PMID: 31011892]|
|||Karr S, Epidemiology and management of hyperlipidemia. The American journal of managed care. 2017 Jun [PubMed PMID: 28978219]|
|||Grundy SM,Stone NJ,Bailey AL,Beam C,Birtcher KK,Blumenthal RS,Braun LT,de Ferranti S,Faiella-Tommasino J,Forman DE,Goldberg R,Heidenreich PA,Hlatky MA,Jones DW,Lloyd-Jones D,Lopez-Pajares N,Ndumele CE,Orringer CE,Peralta CA,Saseen JJ,Smith SC Jr,Sperling L,Virani SS,Yeboah J, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Jun 25 [PubMed PMID: 30423393]|
|||Pears R,Griffin M,Futema M,Humphries SE, Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia. Current opinion in lipidology. 2015 Jun; [PubMed PMID: 25887683]|
|||Paquette M,Chong M,Thériault S,Dufour R,Paré G,Baass A, Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. Journal of clinical lipidology. 2017 May - Jun; [PubMed PMID: 28456682]|
|||Paththinige CS,Sirisena ND,Dissanayake V, Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review. Lipids in health and disease. 2017 Jun 2; [PubMed PMID: 28577571]|
|||Ghaleb Y,Elbitar S,El Khoury P,Bruckert E,Carreau V,Carrié A,Moulin P,Di-Filippo M,Charriere S,Iliozer H,Farnier M,Luc G,Rabès JP,Boileau C,Abifadel M,Varret M, Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia? European journal of human genetics : EJHG. 2018 Apr; [PubMed PMID: 29374275]|
|||Thériault S,Lali R,Chong M,Velianou JL,Natarajan MK,Paré G, Polygenic Contribution in Individuals With Early-Onset Coronary Artery Disease. Circulation. Genomic and precision medicine. 2018 Jan; [PubMed PMID: 29874178]|
|||Sharifi M,Higginson E,Bos S,Gallivan A,Harvey D,Li KW,Abeysekera A,Haddon A,Ashby H,Shipman KE,Cooper JA,Futema M,Roeters van Lennep JE,Sijbrands EJG,Labib M,Nair D,Humphries SE, Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia. Atherosclerosis. 2017 Aug; [PubMed PMID: 28549500]|
|||Xu RX,Wu YJ, Lipid-Modifying Drugs: Pharmacology and Perspectives. Advances in experimental medicine and biology. 2020; [PubMed PMID: 32246446]|
|||Toth PP,Banach M, Statins: Then and Now. Methodist DeBakey cardiovascular journal. 2019 Jan-Mar [PubMed PMID: 31049146]|
|||Filippatos TD,Panagiotopoulou T,Tzavella E,Elisaf MS, Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Journal of cardiovascular pharmacology and therapeutics. 2018 May; [PubMed PMID: 29409336]|
|||Rosenson RS,Hegele RA,Fazio S,Cannon CP, The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology. 2018 Jul 17 [PubMed PMID: 30012326]|
|||Lent-Schochet D,Jialal I, Antilipemic Agent Bile Acid Sequestrants . 2020 Jan [PubMed PMID: 31751096]|
|||Sizar O,Talati R, Ezetimibe . 2020 Jan [PubMed PMID: 30422474]|